The new site is five miles from Avid’s existing operations in Tustin, California.
Avid has also appointed Drew Brennan, a senior CDMO business development executive, as general manager of viral vector technologies to lead its expansion into the cell and gene therapy market.
Respond to the request
The cell and gene therapy market has experienced continued strong growth; and yet, the CDMO industry still lacks the expertise and capability to manufacture proven, high-quality CGMPs for viral vectors, Avid says. This prompted his decision to expand into the development and manufacture of viral vectors.
The company expects full construction of the new facility to take up to 18 months, at a cost of $ 65 million to $ 75 million. The analytical and process development labs are expected to go online sooner and could be operational within six to eight months.
This investment in viral vector services follows recent initiatives by Avid to increase its existing biologics manufacturing capacity through continued expansions of its Myford manufacturing facility. The expansion in viral vector services, combined with Myford’s ongoing expansion, has the potential to bring the company’s total annual revenue generation capacity to over $ 350 million.
As the new Managing Director of Viral Vector Technologies, Brennan will be responsible for overseeing all business activities related to Avid’s expansion into the cell and gene therapy market. He joins Avid after more than a decade in commercial and operational leadership roles at Novasep, a provider of equipment and services in the areas of production and purification of small molecules and biologics for the life sciences. life and chemical industries.
Nicholas Green, President and CEO of Avid Bioservices, said: “We believe that the addition of viral vector services is a natural extension of our existing offering of traditional biologics and provides another avenue for growth by supporting the development and manufacture of these innovative therapies. We are also excited to add Drew to our team to lead our commercial efforts in the cell and gene therapy market. His impressive track record in this field, combined with the close relationships he has developed across the industry, will strongly position this new service offering for success.